The cumulative incidence of nasopharyngeal carcinoma per 100,000 person-years was 11.2 among subjects who had no serologic markers of EBV, 45.0 among those who had one marker, and 371.0 among ...

Expression of YB-1 In Vitro. CNE-2 nasopharyngeal cancer cells were found to have a higher level of YB-1 mRNA expression although not statistically significant as compared to MDA-MB-231 breast ...

BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...

These records were searched for several tumor markers at the time of cancer diagnosis (± 1.5 months), including CEA, CA 19-9, CA125, AFP, LDH, uric acid, and alkaline phosphatase. Results: A total of ...

Individuals who are at high risk for nasopharyngeal carcinoma may benefit from screening using circulating cell–free Epstein-Barr virus (EBV) DNA, suggest researchers from China. This cancer has ...

Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in ...

Distinct tumor immune microenvironments (TIME) characterize subtypes of locoregionally advanced nasopharyngeal carcinoma, influencing disease progression and treatment response.

Source Reference: Castle PE, Han PKJ "On the nose: reducing nasopharyngeal cancer-related mortality using risk-based Epstein-Barr virus serology screening" J Clin Oncol 2024; DOI: 10.1200/JCO.23. ...

Nasopharyngeal cancer is when abnormal cells in the nasopharynx start to divide and grow in an uncontrolled way. The cells can grow into surrounding tissues or organs and may spread to other areas of ...

The precise origin of nasopharyngeal cancer remains unclear, but researchers have identified several contributing factors. One of the primary nasopharyngeal cancer causes is infection with the ...

Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. P Bossi and others. Annals of Oncology, 2021. Volume 32, Issue 4, Pages 452-465.